Similar Papers

Paper Title
Journal
Date
Author
Early-phase clinical drug development of novel agents: a changing paradigm.
M De Miguel ... E Calvo
Annals of Oncology | VOL. 30
M De Miguel, et. al.M De Miguel ... E Calvo
01 Jul 2019
Abstract B141: Combining the telomerase peptide cancer vaccine UV1 with CTLA-4 blockade in patients with metastatic malignant melanoma: Proof of principle and early clinical reports from a phase I/IIa trial
Elin Aamdal ... Steinar Aamdal
Cancer Immunology Research | VOL. 4
Elin Aamdal, et. al.Elin Aamdal ... Steinar Aamdal
01 Jan 2015
Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab.
Marko Kurnik ... Matej Podbregar
Immunotherapy | VOL. -
Marko Kurnik, et. al.Marko Kurnik ... Matej Podbregar
16 Nov 2024
Abstract P216: IK-930 mediated TEAD inhibition decreases and delays tumor growth and enhances targeted apoptosis in lung and colon cancer xenografts when combined with MEK or EGFR inhibitors
Benjamin Amidon ... Karen Mcgovern
Molecular Cancer Therapeutics | VOL. 20
Benjamin Amidon, et. al.Benjamin Amidon ... Karen Mcgovern
01 Dec 2021
View more papers

More From: Pigment Cell & Melanoma Research

Paper Title
Journal
Date
Author
-
-
Pigment Cell & Melanoma Research | VOL. 38
--
01 Jan 2025
The Incorporation of Melanosomes by Senescent Keratinocytes Causes the Accumulation of Melanin due to Decreased Energy Metabolism
Hiroko Yamazaki ... Hideya Ando
Pigment Cell & Melanoma Research | VOL. 38
Hiroko Yamazaki, et. al.Hiroko Yamazaki ... Hideya Ando
01 Jan 2025
Issue Information
-
Pigment Cell & Melanoma Research | VOL. 38
--
19 Dec 2024
-
-
Pigment Cell & Melanoma Research | VOL. 37
--
01 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.